Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07561814

A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data

The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.

The main questions it aims to answer are:

* Can combining these types of data more accurately estimate how long a person might survive? * Can it better predict the risk of recurrence?

Participants will not have any extra tests or treatments. They will:

* Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results) * Receive a follow-up phone call for up to 3 years to share health updates（about every 3 months for the prospective cohort）.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongshan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China

Location status: Recruiting

Location contact

Dongjie Chen

CONTACT

[email protected]

18221994497

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Histologically or cytologically confirmed diagnosis of pancreatic cancer.
  • Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.
  • Underwent surgical treatment for pancreatic cancer at a participating center of this study.

Exclusion criteria

  • Age < 18 years (minors).
  • Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;
  • patients unable to comply with follow-up or provide informed consent.
  • Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.

Treatment and study plan

Primary outcomes

  1. overall survival

    Time frame: 3 years

  2. recurrence free survival

    Time frame: 3 years

  3. recurrence status within one year after surgery

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University
  • The First Affiliated Hospital of University of South China

Registry information

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
May 1, 2026
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.